• ChemFaces is a professional high-purity natural products manufacturer.
  • Product Intended Use
  • 1. Reference standards
  • 2. Pharmacological research
  • 3. Inhibitors
  • Home
  • Natural Products
  • Bioactive
  • Screening Libraries
  • Hot Products
  • Plant Catalog
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • Natural Products
    CAS No. 134418-28-3 Price $40 / 20mg
    Catalog No.CFN99770Purity>=98%
    Molecular Weight332.43Type of CompoundDiterpenoids
    FormulaC20H28O4Physical DescriptionWhite powder
    Download Manual    COA    MSDSSimilar structuralComparison (Web)
    How to Order
    Orders via your E-mail:

    1. Product number / Name / CAS No.
    2. Delivery address
    3. Ordering/billing address
    4. Contact information
    Sent to Email: info@chemfaces.com
    Contact Us
    Order & Inquiry & Tech Support

    Tel: (0086)-27-84237683
    Fax: (0086)-27-84254680
    E-mail: manager@chemfaces.com
    Address: No. 83, CheCheng Rd., WETDZ, Wuhan, Hubei 430056, PRC
    Delivery time
    Delivery & Payment method

    1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

    2. We accept: Wire transfer & Credit card & Paypal & Western Union
    * Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
    Our products had been exported to the following research institutions and universities, And still growing.
  • Helmholtz Zentrum München (Germany)
  • University of Otago (New Zealand)
  • University of Bonn (Germany)
  • University of Hull (United Kingdom)
  • University of Illinois (USA)
  • Celltrion Chemical Research Inst... (Korea)
  • Universitas Airlangga (Indonesia)
  • University of Perugia (Italy)
  • Medical University of South Caro... (USA)
  • Mahatma Gandhi University (India)
  • Lund University (Sweden)
  • More...
  • Package
    Featured Products
    Moracin P

    Catalog No: CFN92324
    CAS No: 102841-46-3
    Price: $418/5mg

    Catalog No: CFN92169
    CAS No: 102607-41-0
    Price: $498/5mg

    Catalog No: CFN92232
    CAS No: 15358-48-2
    Price: $513/5mg

    Catalog No: CFN98105
    CAS No: 82854-37-3
    Price: $60/20mg
    Picroside III

    Catalog No: CFN99567
    CAS No: 64461-95-6
    Price: $228/20mg
    Biological Activity
    Description: Dehydroandrographolide is a novel TMEM16A inhibitor and possesses multiple pharmacological activities, including anti-inflammation, anti-cancer, anti-bacterial, anti-virus and anti-hepatitis activity. It possesses activity against HBV DNA replication with IC50 values of 22.58 uM and low SI values of 8.7 ; it can alleviate oxidative stress in LPS-induced acute lung injury possibly by inactivating iNOS.
    Targets: IL Receptor | NOS | TNF-α | p38MAPK | HBV
    In vitro:
    DARU., 2015, 23(1):1-7.
    Dehydroandrographolide enhances innate immunity of intestinal tract through up-regulation the expression of hBD-2.[Pubmed: 26223251]
    Dehydroandrographolide (DA) is one of major active components in the well-known oriental herbal medicine Andrographis paniculata (Burm.f) Nees which belongs to the Acanthaceae family. DA is used for the treatment of infections in China. However, DA has not been found to significantly inhibit bacterial and viral growth directly. The current study investigates the effect of DA on the expression of human β -defensin-2 (hBD-2) in human intestinal epithelial cells and the possible signaling pathways.
    Human intestinal epithelial HCT-116 cells were incubated with 1-100 μM DA for 2-24 h. RT-PCR and Western blot were used to assess the expression of hBD-2. The specific inhibitors were used and the levels of phosphorylation of signaling molecules were detected for dissecting the signaling pathways leading to the induction of hBD-2. MTT assay showed there was no obvious cytotoxicity for HCT-116 cells by 1-100 μM DA treatment. RT-PCR and Western blot assays showed that DA (1-100 μM) could up-regulate the expression of hBD-2, and the effect lasted longer than 24 h. By using SB203580 and SB202190 (inhibitors of p38), the enhancement of hBD-2 expression were significantly attenuated. However, inhibitor of ERK and inhibitor of JNK could not block the effect of DA. Furthermore, Western blot found activation of p38 but not ERK and JNK in DA-treated HCT-116 cells.
    The results suggested that DA enhanced innate immunity of intestinal tract by up-regulating the expression of hBD-2 through the p38 MAPK pathways.
    Bioorg Med Chem Lett. 2014 May 15;24(10):2353-9.
    Synthesis, structure-activity relationships and biological evaluation of dehydroandrographolide and andrographolide derivatives as novel anti-hepatitis B virus agents.[Pubmed: 24731274]
    Dehydroandrographolide and andrographolide, two natural diterpenoids isolated from Andrographis paniculata possessed activity against HBV DNA replication with IC50 values of 22.58 and 54.07μM and low SI values of 8.7 and 3.7 in our random assay.
    Consequently, 48 derivatives of Dehydroandrographolide and andrographolide were synthesized and evaluated for their anti-HBV properties to yield a series of active derivatives with lower cytotoxicity, including 14 derivatives against HBsAg secretion, 19 derivatives against HBeAg secretion and 38 derivatives against HBV DNA replication. Interestingly, compound 4e could inhibit not only HBsAg and HBeAg secretions but also HBV DNA replication with SI values of 20.3, 125.0 and 104.9. Furthermore, the most active compound 2c with SI value higher than 165.1 inhibiting HBV DNA replication was revealed with the optimal logP value of 1.78 and logD values.
    Structure-activity relationships (SARs) of the derivatives were disclosed for guiding the future research toward the discovery of new anti-HBV drugs.
    In vivo:
    Chin J Integr Med. 2014 Dec 9.
    Potassium Dehydroandrographolide Succinate Injection for the treatment of child epidemic parotitis: A systematic review and meta-analysis.[Pubmed: 25491538]
    To systematically evaluate the clinical efficacy and safety of Potassium Dehydroandrographolide Succinate Injection (PDSI) in the treatment of child epidemic parotitis (EP).
    Randomized controlled trials (RCTs) regarding Potassium Dehydroandrographolide Succinate Injection in the treatment of child EP were searched in China National Knowledge Infrastructure, Wanfang Database, Chinese Biomedical Literature Database, PubMed, and Cochrane Library from inception to July 30, 2013. Two reviewers independently retrieved RCTs and extracted information. The Cochrane risk of bias method was used to assess the quality of included studies, and a metaanalysis was conducted with RevMan 5.2 software. A total of 11 studies with 818 participants were included. The quality of the studies was generally low, among which only one study mentioned the random method. The meta-analysis indicated that Potassium Dehydroandrographolide Succinate Injection was more effective than the conventional therapy with Western medicine for EP in the outcomes of the total effective rate [relative risk (RR)=1.23, 95% confidence interval (CI) [1.14, 1.33], P<0.01], the time of temperature return to normal, the time of detumescence [mean difference (MD)=-2.10, 95% CI [-2.78, -1.41], P<0.01], and the incidence of complications (RR=0.14, 95% CI [0.03, 0.72], P=0.02). There were 6 adverse drug reactions (ADRs) in this systematic review, 2 of which were mainly represented rash and diarrhea in the experiment group, while another 4 ADRs occurred in the control group.
    Based on the systematic review, Potassium Dehydroandrographolide Succinate Injection was effectiveness and relatively safety in the treatment of child EP. But further rigorously designed trials are warranted to determine its effectiveness.
    Dehydroandrographolide Description
    Source: The herbs of Andrographis paniculata (Burm. f.) Nees
    Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
    Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

    After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
    Recent ChemFaces New Products and Compounds

    Catalog No: CFN92750
    CAS No: 5989-02-6
    Price: $388/5mg
    Ginsenoside F5

    Catalog No: CFN95034
    CAS No: 189513-26-6
    Price: $298/20mg

    Catalog No: CFN98531
    CAS No: 27210-57-7
    Price: $288/5mg
    Gypenoside XVII

    Catalog No: CFN90193
    CAS No: 80321-69-3
    Price: $148/20mg
    Arteannuin B

    Catalog No: CFN98807
    CAS No: 50906-56-4
    Price: $228/20mg

    Catalog No: CFN91054
    CAS No: 2449-39-6
    Price: $318/5mg

    Catalog No: CFN98488
    CAS No: 3602-54-8
    Price: $100/5mg

    Catalog No: CFN95106
    CAS No: 38274-00-9
    Price: $388/5mg
    Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.

    PMID: 29328914

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.

    PMID: 29149595

    Scientific Reports 2017 Dec 11;7(1):17332.
    doi: 10.1038/s41598-017-17427-6.

    PMID: 29230013

    Molecules. 2017 Oct 27;22(11). pii: E1829.
    doi: 10.3390/molecules22111829.

    PMID: 29077044

    J Cell Biochem. 2018 Feb;119(2):2231-2239.
    doi: 10.1002/jcb.26385.

    PMID: 28857247

    Phytomedicine. 2018 Feb 1;40:37-47.
    doi: 10.1016/j.phymed.2017.12.030.

    PMID: 29496173
    Calculate Dilution Ratios(Only for Reference)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 3.0082 mL 15.0408 mL 30.0815 mL 60.163 mL 75.2038 mL
    5 mM 0.6016 mL 3.0082 mL 6.0163 mL 12.0326 mL 15.0408 mL
    10 mM 0.3008 mL 1.5041 mL 3.0082 mL 6.0163 mL 7.5204 mL
    50 mM 0.0602 mL 0.3008 mL 0.6016 mL 1.2033 mL 1.5041 mL
    100 mM 0.0301 mL 0.1504 mL 0.3008 mL 0.6016 mL 0.752 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    Animal Research:
    Nan Fang Yi Ke Da Xue Xue Bao. 2012 Sep;32(9):1238-41.
    [Dehydroandrographolide succinate inhibits oxidative stress in mice with lipopolysaccharide-induced acute lung injury by inactivating iNOS].[Pubmed: 22985554]
    To investigate the effect of Dehydroandrographolide succinate (DAS) on oxidative stress and induced nitric oxide synthase (iNOS) expression in a mouse model of lipopolysaccharide (LPS)-induced acute lung injury.
    Thirty male BALB/C mice were randomly divided into control group, LPS+DAS group and LPS group (n=10). The levels of interleukin-1β (IL-1β), IL-6, tumor necrosis factor-α (TNF-α), malondialdehyde (MDA) and superoxide dismutase (SOD) in the bronchoalveolar lavage fluid (BALF) were measured. The wet-to-dry ratio (W/D) of the lung tissue was determined to evaluate lung edema. HE staining was used to observe the pathological changes and lung injury scores. The expressions of iNOS mRNA and protein in the lungs were analyzed using RT-PCR and Western blotting, respectively. IL-1β, IL-6, TNF-α and MDA levels in the BALF, W/D, lung injury scores, and iNOS mRNA and protein expressions increased and SOD in the BALF decreased significantly after intratracheal LPS injection. Compared with those in LPS group, IL-1β, IL-6, TNF-α and MDA in BALF, W/D, lung injury scores and iNOS mRNA and protein expression were significantly reduced and SOD in the BALF significantly increased in LPS+DAS group.
    Dehydroandrographolide succinate can alleviate oxidative stress in LPS-induced acute lung injury possibly by inactivating iNOS.